A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease

LaTonya J. Hickson1,2,3 | Tala Abedalqader2 | Gift Ben-Bernard2 | Jayla M. Mondy2 | Xiaohui Bian1 | Sabena M. Conley1 | Xiangyang Zhu2 | Sandra M. Herrmann2 | Aleksandra Kukla2 | Elizabeth C. Lorenz2,3 | Seo Rin Kim2 | Bjorg Thorsteinsdottir3,4 | Lilach O. Lerman2 | M. Hassan Murad3,4

1Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, Florida
2Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota
3Kern Center Affiliate, Mayo Clinic, Rochester, Minnesota
4Division of Preventive Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota

Correspondence
LaTonya J. Hickson, MD, Division of Nephrology and Hypertension, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224. Email: hickson.latonya@mayo.edu

Present address
Tala Abedalqader, Alfaisal University, Riyadh, Saudi Arabia
Jayla M. Mondy, Mississippi State University, Starkville, Mississippi, Xiaohui Bian, Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China
Seo Rin Kim, Pusan National University Yangsan Hospital, Yangsan-si, Korea

Funding information
Burroughs Wellcome Fund; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery; Mayo Clinic CCaTS, Grant/Award Number: UL1TR002377; NIDDK Diabetes Complications Consortium, Grant/Award Numbers: DK115255, DK076169; National Institutes of Health (NIH), Grant/Award Numbers: DK101405, DK118120, DK07013, DK102325, DK123492, DK109134; Mayo Clinic Florida Center for Regenerative Medicine; Regenerative Medicine Minnesota, Grant/Award Number: RMM 091718CT

Abstract
Regenerative, cell-based therapy is a promising treatment option for diabetic kidney disease (DKD), which has no cure. To prepare for clinical translation, this systematic review and meta-analysis summarized the effect of cell-based interventions in DKD animal models and treatment-related factors modifying outcomes. Electronic databases were searched for original investigations applying cell-based therapy in diabetic animals with kidney endpoints (January 1998-May 2019). Weighted or standardized mean differences were estimated for kidney outcomes and pooled using random-effects models. Subgroup analyses tested treatment-related factor effects for outcomes (creatinine, urea, urine protein, fibrosis, and inflammation). In 40 studies (992 diabetic rodents), therapy included mesenchymal stem/stromal cells (MSC; 61%), umbilical cord/amniotic fluid cells (UC/AF; 15%), non-MSC (15%), and cell-derived products (13%). Tissue sources included bone marrow (BM; 65%), UC/AF (15%), adipose (9%), and others (11%). Cell-based therapy significantly improved kidney function while reducing injury markers (proteinuria, histology, fibrosis, inflammation, apoptosis, epithelial-mesenchymal-transition, oxidative stress). Preconditioning, xenotransplantation, and disease-source approaches were effective. MSC and UC/AF cells had greater effect on kidney function while cell products improved fibrosis. BM and UC/AF tissue sources more effectively improved kidney function and proteinuria vs adipose or other tissues. Cell dose, frequency, and administration route also imparted different benefits. In conclusion, cell-based interventions in diabetic animals improved kidney function and reduced injury with treatment-related factors modifying these effects. These findings may aid in development of optimal repair...
Diabetic kidney disease (DKD), the leading cause of end-stage kidney disease in the United States, has no adequate cure. Regenerative, cell-based therapies such as mesenchymal stromal cells (MSC), the most extensively studied cells, facilitate kidney repair through paracrine-mediated actions, including release of extracellular vesicles, and cell-cell interactions reactivating endogenous repair systems. In the injured kidney, MSC release antifibrotic and antiapoptotic (ie, hepatocyte growth factor [HGF]), pro-angiogenic (ie, vascular endothelial growth factor), and anti-inflammatory (ie, indoleamine 2,3 deoxyxigenase; prostaglandin E2) soluble mediators. Furthermore, peripheral delivery of cells induces reparative effects. Proposed mechanisms include the engulfment of apoptotic MSC by macrophages which promote an anti-inflammatory macrophage phenotype switch associated with interleukin (IL)-10 release that dampens the inflammatory response. Collectively, these reparative actions by MSC, other stem cells, and cell-derived products reduce glomerulosclerosis, interstitial fibrosis, tubulointerstitial inflammation, and oxidative stress in the damaged kidney.

In addition to DKD, these reparative effects have been demonstrated in several animal models of kidney disease, including renovascular disease, lupus nephritis, chemotherapy-induced injury, acute kidney injury, and kidney transplantation. Cell-based therapies were safe, reduced kidney injury, and improved kidney function therein providing preclinical evidence supporting clinical trial pursuits in humans with DKD. Earlier attempts to quantitatively summarize cell-based therapy effects in experimental DKD were limited by a small number of available studies. Yet, stem cell-based therapies improved kidney function, proteinuria, metabolic parameters, and kidney/body weight in diabetic animals (n = 8 original studies). In the last decade, the number of investigations in animal models of DKD has more than tripled. Collectively, these encouraging studies provided the basis for a single early-phase clinical trial in DKD and others are currently underway (NCT02585622, NCT03840343, NCT04869761, NCT04125329, NCT04216849, NCT02008851, NCT03270956, NCT02836574).

A better understanding of the impact of numerous treatment-related factors on regenerative, cell-based therapy approaches in DKD is needed. First, the most optimal cell dose, number of administrations, and delivery route have yet to be determined. Second, exploitation of stem cell paracrine-mediated activities using cell-derived products, such as extracellular vesicles and conditioned medium, has not been fully explored. Third, the pro-apoptotic, DKD microenvironment reduces stem cell function and vitality thus novel preconditioning strategies and alternative delivery methods are being actively pursued. Fourth, feasibility of cells harvested from diseased (autologous) host sources requires additional testing. Each of these treatment-related factors may influence effects of cell-based therapy on kidney outcomes.

The current pool of available studies now affords an opportunity to summarize the effect of cell-based therapy in experimental models of DKD and gain better understanding of how treatment-related factors may influence DKD outcomes. These findings may offer direction for new interventions in experimental models of DKD and inform the translation of cell-based therapies to clinical trials. Thus, the aim of this systematic review and meta-analysis project was to evaluate the regenerative effect of cell-based therapies in animal models of DKD and to determine the impact of treatment-related factors on kidney outcomes.

**Significance statement**

This systematic review and meta-analysis quantitatively summarizes the therapeutic effect and factors influencing regenerative, cell-based therapies in experimental diabetic kidney disease (DKD). In 40 studies (992 diabetic rodents), infusion of mesenchymal stromal cells, umbilical cord/amniotic fluid cells, other tissue-derived cells, or cell products improved kidney function while reducing kidney injury markers (proteinuria, fibrosis, inflammation, apoptosis, epithelial-mesenchymal transition, histology, and oxidative stress) and supporting repair. Approaches incorporating preconditioning, xenotransplantation, and disease-source strategies were also effective. Notably, treatment-related factors, such as cell type, tissue source, source health, dose, and infusion route, influenced cell-based therapy effects on kidney outcomes. Collectively, these findings provide evidence of the therapeutic benefit derived by cell-based therapy in DKD and may inform experimental and clinical translation of these findings.
2 | MATERIALS AND METHODS

2.1 | Data sources and searches

A systemic review and meta-analysis was conducted to examine the effects of cell and cell-based therapies on kidney outcomes measures in animal models of diabetes. We searched for studies published between January 1, 1998 and May 3, 2019 in MEDLINE, Embase, Web of Science, and Scopus. Database searches were adapted from Papazova et al and formatted for DKD query (Material S1 in Supporting Information).

2.2 | Study selection

Search results yielded 699 English language articles which were subjected to initial screening of titles and abstracts with full-text reviews for clarification (L.J.H., J.M.M.). Articles were initially prescreened for content that included regenerative, cell-based therapy studies in animal models of diabetes which contained kidney outcomes. Regenerative therapies applied in nondiabetes conditions and human studies were excluded. Nonoriginal investigations, including conference abstracts, reviews, systematic reviews, and meta-analyses, were excluded but used to search for additional articles.

Eligibility was then assessed in the remaining 51 articles (Figure 1). Initial full text reviews were independently conducted in first (X.B., S.M.C., S.M.H., X.Z., A.K.) and second (J.M.M., T.A., L.J.H., G.B.-B.) rounds to assess inclusion and exclusion criteria below. In the case of disagreement, a third review was performed (L.J.H.). Final study cohort was reviewed by the team. Out of the 51 articles, 40 studies were included in the final qualitative and quantitative synthesis.

2.2.1 | Inclusion criteria

Studies meeting all three inclusion criteria were appraised and analyzed. Inclusion criteria were: (a) original investigation in animals with diabetes, (b) cell or cell-based therapy intervention, and (c) kidney outcome measures reported postintervention.

2.2.2 | Exclusion criteria

Articles undergoing full-text reviews were excluded for the following reason(s): (a) fewer than three animals in treatment/intervention group(s), (b) lack of appropriate diabetes control group, (c) cell-based intervention using irradiation and/or bone-marrow transplantation.

Figure 1: PRISMA flow diagram of study selection criteria and kidney outcomes. The studies were selected according to the inclusion and exclusion criteria. Titles and abstract were initially screened, followed by more in-depth full-text reviews.
procedure, or (d) incomplete or illegible data or figures preventing data abstraction and comparison to other studies.

2.3 Data extraction and quality assessment

Study characteristics captured included animal demographics, experimental groups, diabetes induction, cell type, and kidney-based outcomes. Animal demographics included species, strain, sex, and diabetes model. Cell/cell product data included: cell type (or cell product including exosomes, extracellular vesicles, or microvesicles, and conditioned medium), tissue source, and host source (within species or xenotransplantation from humans), and host source health (diseased or healthy). Manipulation of animal exposures (ie, cyclosporine or xenotransplantation from humans), and host source health (disconditioned medium), tissue source, and host source (within species or xenotransplantation from humans), and host source health (diseased or healthy). Manipulation of animal exposures (ie, cyclosporine gavage) and cell manipulations were captured. MSC are differentiated from other multipotent cells as defined by criteria provided by the International Society for Cellular Therapy. Preconditioning methods, homing methods (ie, ultrasound-targeted microbubble destruction), and cell sorting were collectively grouped as “preconditioning” for the subgroup analyses. Cell treatment-related data included cell number per dose administration, dosing frequency, dosing number, and route of cell delivery. Cell-based interventions were also categorized as preventative if therapy was given before or during induction of diabetes (0-6 days for induction models) or rescue if the intervention was given after initiation of the diabetic model. The duration of follow-up was captured for each animal.

Kidney-based outcomes in blood, urine, or kidney tissue samples included: plasma creatinine, plasma urea (or blood urea nitrogen [BUN]), urinary protein (or albumin), glomerular filtration rate/creatinine clearance, renal histology, blood pressure (BP), kidney injury markers (including glomerular/mesangial histologic changes, markers of inflammation, fibrosis, apoptosis, oxidative stress, and epithelial-to-mesenchymal transition [EMT]). For the primary analyses, measurements from the latest time point after cell intervention were used. Measurements were abstracted at various time points following cell intervention (early (<4 weeks), middle (4-7 weeks), and late (≥8 weeks) when reported.

The control (including animals receiving anti-diabetes therapy) and experimental groups were compared. BUN measurements were converted to urea (mg/dL). Plasma and serum creatinine were converted to mg/dL. Proteinuria and albuminuria were converted to mg per 24 hours. Urine albumin-to-creatinine ratio (UACR) data were uniformly converted to μg/mg. In studies that reported multiple measurements of urine protein excretion, only one was included in the final analysis, with the default being UACR when available.

All outcomes were captured as %change or in actual units. Data were collected from article text and tables. Article authors were contacted by email to request missing data. Results in graphs were abstracted using WebPlotDigitizer v.4.1 (Austin, Texas) software. Data extraction was done independently by two reviewers (J.M.M., T.A.) with a third reviewer (G.B.-B.) for quality control. The SEM was uniformly converted to SD (SD = SD / n × SEM).

Assessment of the reporting quality of included studies was performed using a scoring system adapted from Papazova et al and Wever et al. Evaluation of risk of bias was performed using Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) risk of bias tool. Funnel plot was produced for creatinine outcome to assess the potential for publication bias. Scoring of quality assessment (G.B.-B., J.M.M.) and risk of bias (G.B.-B., T.A.) were performed by two independent reviewers with a third reviewer (L.J.H.) for discrepancies.

2.4 Data synthesis and analysis

Outcomes were estimated as weighted mean difference (WMD) for creatinine, urea, and BP as these outcomes were measured consistently across studies and were presented in natural units. Urine protein excretion measures (UACR, albuminuria, proteinuria) were grouped and reported as a standardized mean difference (SMD). For all other kidney outcomes, results were expressed as SMD with 95% confidence intervals (CIs) due to heterogeneity of measurement methods. Random-effects model (RE) was used to conduct meta-analysis due to heterogeneity across studies. Heterogeneity was expressed using the (I²) index. I² > 50% was considered to suggest substantial heterogeneity.

Though multiple injury markers were analyzed, five outcomes were considered primary outcomes of interest (creatinine, urea, proteinuria, fibrosis, and inflammation). Subgroup-analyses of these primary outcomes were performed to assess the animal- and treatment-related effects of cell-based therapy. For animal-related effect analyses, species (rat, mouse, tree shrew), sex (male, female), and diabetes induction (Streptozotocin [STZ], db/db, other) were compared. Treatment-related effect analyses included: cell type (MSC, umbilical cord/anniotic fluid cells [UC/AF], non-MSC, cell products), tissue source (bone marrow [BM], adipose, UC/AF, other), host source (within species, xenotransplant), host source’s health (healthy, disease), cell manipulation (standard culture medium, preconditioning/homing/management methods), route of delivery (tail vein, other), cell dose total (low [<10⁵ cells], medium [10⁵-10⁶ cells], high [>10⁷ cells]), outcome reporting times (early [<4 weeks], middle [4-7 weeks], and late [≥8 weeks]), and dosing frequency (single, multiple). Differences between the groups were evaluated using an interaction test as suggested by Altman and Bland. Analysis was conducted using Stata software package (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC).

This systematic review was registered at the International prospective register of systematic reviews (ID: CRD42019136200).

3 RESULTS

3.1 Study selection and characteristics

Electronic search generated 699 articles. After title and abstract reviews, 51 articles underwent full text reviews among which
40 original articles met inclusion criteria (Material S2 in Supporting Information). A total of 992 diabetic animals (438 control; 554 treated) were used to investigate cell-based therapy effects on DKD (Table S1). Studies included 580 rats (59%), 400 mice (40%), and 12 tree shrews (1%) with 840 male and 152 female animals. Three diabetes models were used: streptozotocin (STZ; type 1 diabetes) (81%), genetic defect in leptin receptor (db/db; 11%; type 2 diabetes), and high fat diet (8%; type 2 diabetes). Some studies examined more than one diabetes model per article and others further modified the injury model (ie, STZ plus uric acid).

### 3.2 | Cell-based therapy characteristics

Several cells/products were infused (Table 1). Over half (61%) of studies used MSC followed by UC/AF cells (11%), other cells (Non-MSC 15%), and cell products (extracellular vesicles or conditioned medium; 13%). Tissue sources for cells/products were derived from BM (65%), UC/AF (15%), adipose (9%), and other tissues (dental pulp, liver, pancreas, kidney, urine; 11%). Most studies used allogeneic cells/products (78%) and others were from human hosts (22%; xenotransplant). Cell passage was provided in 32 studies among which the majority utilized cells at passage 3 or fewer (75%), followed by passages 4 to 5 (9.4%) and passages 6 or more (15.6%). In 25 (67.6%) of 37 studies reporting cells at passage 3 or fewer (75%), followed by passages 4 to 5 (9.4%) and passages 6 or more (15.6%). In 25 (67.6%) of 37 studies reporting culture medium, solutions were comprised of a combination of Dulbecco’s Modified Eagle Medium (DMEM) plus 10% to 20% fetal calf serum, kidney, urine; 11%). Most studies used allogeneic cells/products (78%) and others were from human hosts (22%; xenotransplant). Cell passage was provided in 32 studies among which the majority utilized cells at passage 3 or fewer (75%), followed by passages 4 to 5 (9.4%) and passages 6 or more (15.6%). In 25 (67.6%) of 37 studies reporting culture medium, solutions were comprised of a combination of Dulbecco’s Modified Eagle Medium (DMEM) plus 10% to 20% fetal bovine serum with varying supplements, growth factors, and antibiotics. A healthy host donated cells for nearly all studies (93%) leaving a small minority with diseased (diabetic) hosts. Fifty-nine percent of studies administered cell/product in a single dose, while the remaining studies delivered multiple doses (range: 2-8 doses/animal). A total cell dose less than 1.0 cell/animal was provided in 61% of studies. Cells/prod- uct were delivered to animals through multiple routes (renal subcapsule, intracardiac, peritoneal cavity, jugular vein, renal artery, orbital plexus, and pudendal vein) though tail vein was most common (70%). Rescue therapy was most often used (89%) over preventative approaches. A quarter of studies employed “preconditioning” methods to improve cell function/vitality (Table S2). Cell/animal manipulations consisted of protein overexpression (SIRT3), preconditioning (growth factors, cytokines, umbilical cord extract, melatonin), transfection (microRNA-124a, shRNA against HIF1-a; miRNA-451a), and cell sorting combined with homing (microbubble destruction) or coadministration of cyclosporine to animals.

### 3.3 | Meta-analysis

#### 3.3.1 | Kidney function, histology, and BP

Effects of cell-based therapy are shown for abstracted kidney outcomes (Figure 2). Compared with controls, animals receiving cell-based therapy had improved kidney function as evidenced by reduced serum creatinine (Figure S1) and serum urea. Diabetes-induced renal histological changes, including glomerular size, glomerulosclerosis, and mesangial alterations, were improved. A significant reduction in both systolic and diastolic BP was also found. Heterogeneity was observed for nearly all outcomes ($I^2 \geq 77.9\%$). Overall, cell-based therapy improved kidney function, histology, and BP in animal models of DKD.

#### 3.3.2 | Kidney injury markers (proteinuria, fibrosis, inflammation, apoptosis, oxidative stress, EMT)

Several studies ($n = 32$) examined cell-based therapy effects on urine protein excretion in DKD animals. Among these, three studies had substantial data outliers and were excluded from the meta-analysis.$^{21,32,61}$ Urine protein excretion was reduced in treated animals (Figure S2), specifically UACR (WMD $-60.090$ µg/mg; 95% CI: $-93.730$ to $-26.450$ µg/mg).

| TABLE 1 | Pooled cell types |
|-------|-------------------|
| **Mesenchymal stem/stromal cells (MSC)** | **Umbilical cord and amniotic fluid stem cells (UC/AF)** | **Nonmesenchymal stem/stromal cells (non-MSC)** | **Cell products** |
| Adipose-derived (MSC-Ad) | Amniotic fluid stem cells (AFSC) | Early outgrowth bone marrow cells (EoBMC) | MSC-derived: Exosomes, extracellular vesicles, or microvesicles (MSC-EV) |
| Bone marrow-derived (MSC-BM) | Human umbilical cord blood-derived mononuclear cells (HUCB-SC) | Dental pulp stem cells (DPSC) | Conditioned medium (MSC-CM) |
| Human umbilical cord blood-derived (MSC-hUCB) | Human umbilical cord Wharton jelly cells (HUCWJ) | Myeloid-derived suppressor cells (MDSC) | Other cell-derived: Human-liver stem-like cells (HLSC-EV) |
| **Articles** | | Pancreatic progenitor (fetal) cells | Urine-derived stem cells (USC-EV) |
| Fang 2012 (MSC-Ad) | El-Ashmawy 2018 (HUCB-SC) | Guimaraes et al 2013 (DPSC) | Ebrahim 2018 (MSC-EV) |
| Ni 2015 (MSC-Ad) | Feng (AFSC) | Hsieh 2018 (MDSC) | Grange 2019 (HLSC-EV) and (MSC-EV) |
| Tang 2018 (MSC-Ad) | Maldonado 2017 (HUCWJ) | Jiang 2017 (Pancreatic progenitor) | Jiang 2016 (USC-EV) |
| Zhang 2013-1 (MSC-Ad) | Masood 2012 (HUCB-SC) | Kelly (SRC) | Nagaishi 2016 (MSC-CM) and (MSC) |
| Park 2012-1 (MSC-hUCB) | Park 2012-2 (HUCB-SC) | Zhang 2012 (EoBMC) | Zhong 2019 (MSC-hUC-EV) |
| **All remaining papers** (MSC-BM) | | | |
3.4 | Treatment-related factors affecting kidney outcomes

Five outcomes were considered primary outcomes of interest (creatinine, urea, proteinuria, fibrosis, and inflammation) for which subgroup analyses of animal- and treatment-related effects were performed (Tables S4–S9).

3.4.1 | Cell type

Of the cell groups (MSC, UC/AF, non-MSC, and cell product), only cell product failed to significantly reduce creatinine compared to controls (Table 2). MSC (P < .0001) and UC/AF (P = .05) more effectively reduced creatinine vs non-MSC therapy. All groups reduced urea but no between group differences were observed (P ≤ .7). UC/AF cells were associated with a greater reduction in urine protein compared to MSC (P = .03) or cell product (P = .04), while non-MSC failed to significantly reduce excretion. For fibrosis, product reduced pro-fibrotic markers greater than MSC (P = .03) and UC/AF (P = .03). Notably, UC/AF failed to reduce pro-fibrosis markers.
Finally, MSC consistently altered pro-inflammatory and anti-inflammatory markers. Overall, cell types that emerged as particularly effective included MSC and UC/AF for creatinine, UC/AF for urine protein, and cell product for fibrosis outcomes.

### 3.4.2 | Cell tissue source

Cell tissue sources were grouped as BM, adipose, UC/AF, and other (liver, pancreas, urine, and dental pulp). For both creatinine and urea outcomes, BM and UC/AF induced greater reductions vs adipose ($P \leq .01$; Table 3). Other sources failed to reduce creatinine. Urine protein reduction was greater with UC/AF compared to BM ($P = .03$) but not to other sources ($P = .06$). Other sources reduced pro-fibrotic markers greater than BM ($P = .03$) and adipose ($P = .009$). No differences were observed between sources for inflammation outcomes. Collectively, various tissue sources had notable effects on kidney function (BM, UC/AF), urine protein (UC/AF), and fibrosis (other) outcomes.

### 3.4.3 | Cell donor health

Healthy-source cells exerted greater reductions on creatinine ($P = .002$), urea ($P = .02$), urine protein ($P = .002$), and kidney pro-inflammatory markers ($P = .05$) (Table S11). Surprisingly, based on one study,50 disease-source cells achieved a greater reduction in pro-fibrotic markers vs healthy ($P = .03$).

### 3.4.4 | Cell source species

Comparison of within-species vs xenotransplantation revealed no differential effect between groups for creatinine, fibrosis, and
inflammation outcomes. However, xenotransplantation was associated with greater reduction of urea ($P < .0001$) and urine protein ($P = .03$) compared to within-species group.

### 3.4.5 Delivery route

Tail vein delivery was associated with greater reductions in creatinine ($P \leq .0001$), urea ($P < .0001$) and greater improvement in kidney anti-inflammatory markers ($P \leq .005$) than other routes (Table S12). However, effects on urine protein, pro-fibrotic, and pro-inflammatory markers were not different. Interestingly, antifibrotic makers were increased greater with other (renal artery; $n = 1$)-mediated route ($P < .0001$) compared to tail vein.

### 3.4.6 Dosing regimen

Only pro-fibrotic markers were blunted to a greater degree following multiple vs single dosing regimens ($P = .03$). Other kidney outcomes (creatinine [$P = .7$], urea [$P = .08$], urine protein [$P = .7$], pro-inflammatory [$P = .7$ kidney; $P = .06$ blood], blood anti-inflammatory markers [$P = .9$]) revealed no differential effects between dosing regimens.

### 3.4.7 Dose

Based on the low ($<1.0 \times 10^5$ cells/animal), medium ($1.0 \times 10^5$ to $1.0 \times 10^6$), and high cell dose groupings ($>1.0 \times 10^7$), lower cell dose imparted stronger kidney fibrosis effects compared to the higher doses. Greater dose ($\geq 1.0 \times 10^7$ cells/animal) was associated with a larger reduction in urea ($P = .04$ vs Medium dose; Table S10), whereas lesser dose ($<1.0 \times 10^7$) and medium ($1.0 \times 10^5$ to $1.0 \times 10^6$) reduced pro-fibrotic markers more effectively ($P = .01$ and $P < .001$, respectively) compared to greater dose. No effect differences between groups were observed for creatinine, urine protein, or inflammation markers.
| Cell type     | No. of articles | WMD/SMD [95% CI]          | Comparison group | P value |
|---------------|-----------------|---------------------------|------------------|---------|
| Creatinine (mg/dL) |                 |                           |                  |         |
| MSC           | 13              | −0.29 [−0.36, −0.22]      | MSC vs UC/AF     | .7      |
| UC/AF         | 4               | −0.34 [−0.57, −0.10]      | MSC vs Non-MSC   | <.0001  |
| Non-MSC       | 1               | −0.10 [−0.13, −0.07]      | MSC vs Product   | .7      |
| Cell product  | 2               | −0.41 [−1.03, 0.20]       | Non-MSC vs UC/AF | .05     |
|               |                 |                           | Non-MSC vs Product | .3      |
|               |                 |                           | UC/AF vs Product | .8      |
| Urea (mg/dL)  |                 |                           |                  |         |
| MSC           | 12              | −31.66 [−44.46, −18.85]   | MSC vs UC/AF     | .06     |
| UC/AF         | 3               | −17.32 [−25.22, −9.42]    | MSC vs Non-MSC   | .08     |
| Non-MSC       | 1               | −19.25 [−24.33, −14.17]   | MSC vs Product   | .3      |
| Cell product  | 2               | −59.22 [−105.86, −12.59]  | UC/AF vs Non-MSC | .7      |
|               |                 |                           | UC/AF vs Product | .08     |
|               |                 |                           | Non-MSC vs Product | .09 |
| Urine protein |                 |                           |                  |         |
| MSC           | 20              | −2.38 [−2.97, −1.79]      | MSC vs UC/AF     | .03     |
| UC/AF         | 3               | −26.43 [−48.19, −4.67]    | MSC vs Non-MSC   | .3      |
| Non-MSC       | 2               | −43.85 [−116.81, 29.10]   | MSC vs Product   | .2      |
| Cell product  | 4               | −3.823 [−5.68, −1.96]     | UC/AF vs Non-MSC | .7      |
|               |                 |                           | UC/AF vs Product | .04     |
|               |                 |                           | Non-MSC vs Product | .3      |
| Fibrosis      |                 |                           |                  |         |
| Pro-fibrosis  |                 |                           |                  |         |
| MSC           | 16              | −3.93 [−5.03, −2.83]      | MSC vs UC/AF     | .5      |
| UC/AF         | 2               | −2.50 [−6.68, 1.68]       | MSC vs Non-MSC   | .4      |
| Non-MSC       | 3               | −5.30 [−8.28, −2.32]      | MSC vs Product   | .03     |
| Cell product  | 2               | −9.51 [−14.28, −4.73]     | Non-MSC vs UC/AF | .3      |
|               |                 |                           | Non-MSC vs Product | .1      |
|               |                 |                           | UC/AF vs Product | .03     |
| Antifibrosis  |                 |                           |                  |         |
| MSC           | 3               | 4.01 [0.87, 7.15]         | MSC vs UC/AF     | .1      |
| UC/AF         | 1               | 1.33 [0.15, 2.50]         |                  |         |
| Inflammation  |                 |                           |                  |         |
| Blood pro-inflammation |         |                           |                  |         |
| MSC           | 5               | −2.83 [−3.71, −1.95]      | MSC vs UC/AF     | .7      |
| UC/AF         | 1               | −3.62 [−7.07, −0.18]      |                  | −       |
| Blood anti-inflammation |       |                           |                  | −       |
| MSC           | 2               | 0.99 [0.33, 1.64]         |                  | −       |
| Kidney pro-inflammation |       |                           |                  |         |
| MSC           | 9               | −3.27 [−4.80, −1.74]      |                  | −       |
| UC/AF         |                 |                           |                  | −       |
| Non-MSC       | 1               | −1.22 [−2.60, 0.16]       |                  | −       |
| Cell product  |                 |                           |                  | −       |
| Kidney anti-inflammation |       |                           |                  |         |
| MSC           | 4               | 3.71 [1.65, 5.76]         |                  | −       |
|               |                 |                           |                  | −       |

Note: Bold values are those that are statistically significant.

Abbreviations: CI, confidence interval; MSC, mesenchymal stem cells; Non-MSC, other cells; SMD, standardized mean difference; UC/AF, umbilical cord/amniotic fluid cells; UCB, umbilical cord and amniotic fluid stem cells; WMD, weighted mean difference.
### Outcome timing

A trend was observed for improved outcome effect of lowering serum creatinine (\(P = .06\)) at less than 4 weeks (early) compared to late (\(\geq 8\) weeks). However, no effect difference between timing assessment was determined between early, medium (4-7 weeks), or late (\(\geq 8\) weeks) time points for urea or urine protein excretion. Profibrotic markers demonstrated a trend toward improved antifibrotic activity at late compared to medium outcome timing (\(P = .08\)).

### Table 3

**Effect of treatment-related factors: cell tissue source**

| Cell tissue source | No. of articles | WMD/SMD [95% CI] | Comparison group | \(P\) value |
|--------------------|-----------------|------------------|------------------|-------------|
| **Creatinine (mg/dL)** | | | | |
| BM | 9 | −0.39 [−0.47, −0.30] | BM vs Adipose | <.0001 |
| Adipose | 3 | −0.14 [−0.20, −0.09] | BM vs UC/AF | .7 |
| UC/AF | 6 | −0.035 [−0.56, −0.13] | BM vs Other | <.0001 |
| Other | 2 | −0.07 [−0.21, 0.07] | UC/AF vs Adipose | .07 |
| | | | UC/AF vs Other | .04 |
| | | | Adipose vs Other | .4 |
| **Urea (mg/dL)** | | | | |
| BM | 9 | −30.99 [−46.17, −15.81] | BM vs Adipose | .01 |
| Adipose | 3 | −9.87 [−15.57, −4.18] | BM vs UC/AF | .2 |
| UC/AF | 4 | −44.16 [−57.08, −31.24] | BM vs Other | .2 |
| Other | 2 | −19.72 [−24.73, −14.70] | Adipose vs UC/AF | <.0001 |
| | | | Adipose vs Other | .01 |
| | | | Other vs UC/AF | .005 |
| **Urine protein** | | | | |
| BM | 20 | −2.54 [−3.135, −1.945] | BM vs UC/AF | .03 |
| UC/AF | 4 | −8.32 [−13.57, −3.07] | BM vs Other | .06 |
| Other | 4 | −6.22 [−10.02, −2.42] | UC/AF vs Other | .5 |
| **Fibrosis** | | | | |
| Pro-fibrosis | | | | |
| BM | 15 | −4.34 [−5.56, −3.12] | BM vs Adipose | .2 |
| Adipose | 2 | −2.86 [−4.64, −1.08] | BM vs UC/AF | 1.0 |
| UC/AF | 4 | −4.37 [−7.64, −1.09] | BM vs Other | .03 |
| Other | 2 | −9.61 [−14.32, −4.89] | UC/AF vs Adipose | .4 |
| | | | UC/AF vs Other | .07 |
| | | | Adipose vs Other | .009 |
| Antifibrosis | | | | |
| BM | 2 | 6.84 [−4.02, 17.69] | BM vs UC/AF | .3 |
| UC/AF | 2 | 1.32 [0.49, 2.15] | – | – |
| **Inflammation** | | | | |
| Blood pro-inflammation | | | | |
| BM | 3 | −2.46 [−3.36, −1.55] | BM vs Adipose | .4 |
| Adipose | 2 | −3.43 [−5.53, −1.33] | BM vs UC/AF | .5 |
| UC/AF | 1 | −3.62 [−7.07, −0.18] | Adipose vs UC/AF | .9 |
| Blood anti-inflammation | | | | |
| BM | 2 | 0.99 [0.33, 1.64] | – | – |
| Kidney pro-inflammation | | | | |
| BM | 8 | −3.33 [−5.03, −1.64] | BM vs Adipose | .9 |
| Adipose | 1 | −3.12 [−4.64, −1.61] | BM vs Kidney | .06 |
| Kidney | 1 | −1.22 [−2.60, 0.16] | Adipose vs Kidney | .07 |
| Kidney anti-inflammation | | | | |
| BM | 4 | 3.71 [1.65, 5.76] | – | – |

Note: Bold values are those that are statistically significant.

Abbreviations: BM, bone marrow; CI, confidence interval; SMD, standardized mean difference; UC/AF, umbilical cord/amniotic fluid; WMD, weighted mean difference.
3.4.9 | Cell/animal manipulation

Analyses of “preconditioned” vs standard therapy revealed no differential effect for creatinine ($P = .07$), urea ($P = .8$), urine protein ($P = .9$), pro-fibrosis ($P = .2$), or blood pro-inflammatory markers ($P = .3$). Nevertheless, preconditioning improved pro-inflammatory ($n = 1; P = .02$) and anti-inflammatory kidney markers ($n = 2$) ($P = .05$) compared to standard culture/administered groups.

3.5 | Animal-related factors affecting kidney outcomes

3.5.1 | Animal type

Studies in rats were associated with greater creatinine reduction compared to mice ($P = .004$) or tree shrews ($n = 1; P < .0001$) (Table S13). Rats also had greater urea reduction compared to tree shrews ($P = .009$) but not mice ($P = .3$). Urine protein reduction was greater in rats compared to mice ($P = .003$) but not tree shrews ($P = .1$). Minimal group differences were found in fibrosis and inflammatory outcomes.

3.5.2 | Animal sex

Subgroup analyses yielded no significant effect differences in kidney outcomes between male and female animals ($P = .2$ for all).

3.5.3 | Diabetes model

STZ (type 1 diabetes) was associated with greater reduction in creatinine and urea than db/db ($P = .0001$) or diet ($n = 1; P < .0001$) models (Table S14). No effect differences were noted between STZ and db/db models for fibrosis ($P = .8$) or pro-inflammation (blood $P = .3$; kidney $P = .07$) outcomes.

3.5.4 | Rescue vs prevention timing

Prevention therapy more effectively reduced urine protein ($P = .03$). Yet, rescue therapy more effectively reduced pro-fibrotic markers ($P = .0001$). There were no effect differences between groups for creatinine ($P = .8$), urea ($P = .6$), or antifibrosis ($P = .1$) outcomes.

3.6 | Quality

Quality assessment of all 40 studies was performed using 15 parameters (Figure S4). Ten studies were of high quality (>70% parameters with “yes” response) and none were of low quality (<50% with “yes” responses). Notably, few (10%) studies reported animal baseline characteristics. There was uncertainty as to whether allocation of animals, dropouts, blinding of investigators, and outcome assessors were used for ≥87.5% of the studies. Random allocation of animals was reported in 67.5% of studies. Most studies sufficiently reported data to allow for meta-analyses and potential replication of interventions.

3.7 | Risk of bias

Risk of bias assessment was performed with 10 parameters (Figure S5). Risk of bias was low for selection, reporting, and other sources of bias. The most notable limitations were in performance, detection, and attrition bias primarily due to a lack of studies reporting methodology.

3.8 | Publication bias

Publication bias was evaluated for plasma creatinine, a primary outcome (Figure S6), which did not demonstrate publication bias ($P = .85$ for Egger’s test). However, in the presence of heterogeneity, the statistical assessment of publication bias is unreliable.

4 | DISCUSSION

4.1 | Main findings

This systematic review and meta-analysis of 40 studies demonstrated that cell-based therapy effectively improves kidney function and reduces clinical, serologic, and histologic markers associated with DKD pathogenesis and progression while promoting repair in diabetic animals. Subgroup analyses compared the effects of varying cell types, tissue and host sources, doses, preconditioning methods, and delivery routes in DKD treatment. Notably, MSC and UC/AF cells appear particularly effective in improving kidney function (creatinine, urea), while cell-derived products (extracellular vesicles [EV] and conditioned medium) achieved a more robust decrease in pro-fibrotic marker expression than cell groups. Furthermore, BM and UC/AF sources more effectively improved kidney function and proteinuria compared to adipose and other tissue sources. Collectively, these findings may inform design of future experiments in animals and optimize therapeutic strategies for translation to clinical trials for DKD.

In this meta-analysis, five primary outcomes (creatinine, urea, proteinuria, fibrosis, and inflammation) were ascertained. Yet, other surrogate markers of the complex pathogenesis involved in DKD such as histology (glomerular and mesangial alterations), BP, oxidative stress, apoptosis, and EMT were also captured. In DKD, high systemic glucose is a major inducer of oxidative stress generation, pro-fibrotic pathway activation, and podocyte dysfunction and apoptosis. Activation of the renin-angiotensin-aldosterone system increases BP, promotes inflammation (TNF-α), and activates pro-fibrotic (TGF-β) pathways, including EMT in DKD. These processes result in classic histologic DKD kidney changes in humans and animals such as...
glomerulomegaly,73 glomerulosclerosis, and mesangial expansion74 that closely associate with DKD progression.75 Summarily, kidney fibrosis, fueled by maladaptive inflammation, represents a common final pathway of all chronic kidney disease (CKD).76,77 Each of these pathways were captured in the current meta-analysis which also emphasized effects on individual markers of injury (TGF-β, collagen I, fibronectin, reactive oxidative species, TNF-α, macrophage, and leucocyte infiltration) and repair (E-cadherin, superoxide dismutase, IL-10). This evidence synthesis suggested that cell-based therapy substantially improved injury while simultaneously promoting pro-repair activities in the kidney, blood, and urine in animals, therein targeting multiple pathogenic pathways in DKD.

4.2 Effects of animal- and treatment-related factors

Given lack of consensus for the most optimal cell type/product or therapy regimen in DKD, our subgroup analyses assessed how the choice of diabetes models and cell regimens influenced kidney outcomes. Among animal-related factors, rats (most used) offer an advantage over mice for kidney function and proteinuria outcome effects. Despite concerns that female rodents exhibit less proteinuria,78,79 no sex-related differences were observed for this or other outcomes. STZ-induced diabetes (the primary model in rats) appeared to be advantageous for detecting kidney function effects though no between-group differences (STZ vs db/db or diet models) were found for proteinuria, fibrosis, or inflammation outcomes. Thus, despite concern for potential off-target STZ exposure effects,80,81 cell-based therapy in STZ-rats appear particularly informative while other animals and diabetes models (type 2) also offer insightful findings.

There is still much to be uncovered in the optimization of cell manufacture and delivery for DKD therapy. While MSC represent the most widely studied cells in DKD,82 the current meta-analysis shows that other cell types may have equal effect in improving kidney outcomes. UC/AF cells reduced creatinine, fibrosis, and inflammation like MSC and to a greater degree than non-MSC. UC/AF cells also reduced proteinuria greater than MSC. Surprisingly, cell-derived products were superior for antifibrosis outcomes compared to other cells, despite a limited number of studies. For cell tissue source, BM (most popular) and UC/AF emerged as strong effect modifiers. These findings are particularly relevant given the need for economic considerations.83 UC/AF represents an optimal source tissue for cell/product harvest given the accessibility ease and low harvest costs.7,36,84-87 Only one study directly compared the effectiveness of products (conditioned medium) to MSC,42 and none compared UC/AF to MSC in DKD animals. Finally, processing methods including cell passage number, supplements or growth factors, and fresh vs cryopreserved cells were summarized when available but may influence repair efficiency. Thus, future studies may be warranted to definitively answer superiority of cells vs products and cell tissue source for DKD therapy.

We and others examined efficacy of various cell delivery routes and doses in animal models of CKD.6,18,35,49,88,89 In this meta-analysis, tail vein (70% of studies) was most effective at reducing kidney function outcomes, but antifibrotic factors were more effectively reduced by renal arterial delivery in a single study.27 Prior meta-analyses yielded differing conclusions when comparing systemic/peripheral to intra-arterial delivery. While Papazova et al found no consistent advantage in small and large animals, Wang et al38 deduced that intra-arterial delivery more effectively improved outcomes in small animal models of CKD. Higher cell doses have also been tested in recent years, in this meta-analysis, the higher dose more effectively reduced urea levels but no difference was found in creatinine or urine protein excretion, implying that kidney function is not fully influenced by higher doses. Interestingly, the lower cell dose more effectively reduced fibrosis compared to medium and high cell doses suggesting that greater cell doses are not essential for renal repair in DKD. Several studies have demonstrated the importance of various secreted antifibrotic factors such as HGF and bone morphogenetic protein-7 (BMP-7).29,90,91 In diabetic kidney models, HGF reduced kidney fibrosis through blockade of tubular epithelial cell EMT39 and inhibition of MCP-1 expression, therein reducing kidney macrophage infiltration.29 Intuitively, repeat cell dose increases the exposure time of cells/product, but this meta-analysis identified only pro-fibrotic markers to be more improved with a multiple dosing regimen.

Other findings in xenotransplant and disease-source therapy are also noteworthy. Uniquely, the low immunogenic properties of MSC and other cells/products permitted successful studies in xenotransplantation92-95 Interestingly, xenotransplantation yielded greater reduction in urea and proteinuria compared to the within-species groups. Our study also determined that disease-source cells sufficiently induced renal repair.45 Specifically, Zhang et al40 found that disease-source compared to healthy early outgrowth BM cells were equally effective in reducing glomerular/interstitial fibrosis and oxidative stress. Fang et al4 determined that disease-source MSC inhibited oxidative stress, pro-inflammatory gene expression, and MAPK signaling, a regulator of inflammation, pathway activation. These and other studies provide insightful direction as cell-based therapy is tested in multiple diseases and autologous therapy is entertained.

Given the harsh, DKD microenvironment cells/products encountered after infusion, development of methods to improve delivery and maintain vitality are necessary. In this meta-analysis, preconditioning and other cell/animal manipulations of either disease-source or healthy cells had a robust effect on pro-inflammatory and anti-inflammatory profiles compared to standard treated groups. Moreover, in these studies, preconditioning improved the health of disease cells to comparable efficacy of healthy cells. These findings again support testing of autologous therapy regimens.

For quality assessments, most of the studies were of high quality, no articles were of low quality, and bias risk was low, likely due to the exclusion criteria employed. However, there is room for improvement in reporting/implementing such as random allocation and animal housing that may skew results when measuring outcome parameters.
4.3 | Limitations and strengths

Some limitations exist. To date, current models of DKD parallel only early features of human DKD therein limiting translation.\textsuperscript{30,31,36} However, outcomes assessed in this meta-analysis incorporated markers that are characteristics of advanced human DKD (proteinuria, glomerular/mesangial histology changes, fibrosis, and kidney function).\textsuperscript{36} Additionally, like other studies, this meta-analysis was conducted in the setting of substantial heterogeneity. Wang et al.\textsuperscript{38} found heterogeneity in creatinine outcome to be independently associated with differences in measurement time point and cell therapy delivery route, which cannot be altered. Nonetheless, in the current meta-analysis, beneficial effects of cell-based therapy were consistently shown with 95% CIs frequently overlapping and supporting the findings. Furthermore, use of random-effect analysis limited the risk of reporting erroneous estimates. The strengths of this meta-analysis relate to the comprehensive literature search and independent reviews for study selection and appraisal. Study findings expand upon initial evidence synthesis attempts in DKD\textsuperscript{16} and CKD\textsuperscript{5,38} animals and offer the advantage of including recent, within the last decade, investigations when the regenerative field in DKD has substantially grown.

5 | CONCLUSION

In conclusion, this systematic review and meta-analysis provide insurmountable evidence for the efficacy of cell-based therapy in experimental animal models of DKD. Cell-based therapy improved functional and structural outcomes inherent in DKD pathogenesis and progression for which treatment-related factors further modified this effect. These quantitatively summarized preclinical findings can help guide therapy selection and delivery strategies to aid in successful translation of findings to clinical trials.

ACKNOWLEDGMENTS

The authors thank Patricia J. Erwin, MLS (multi-database literature search); Shane A. Bobart, MD (literature search), Donna K. Lawson, CCRP, LPN (database maintenance), Cody C. Gowan (cell processing reviews), and Shannon Meier (secretarial support). L.J.H. takes full responsibility for the work. This project was supported by funding from Regenerative Medicine Minnesota RMM 091718CT (L.J.H.), Mayo Clinic Florida Center for Regenerative Medicine (L.J.H.), National Institutes of Health (NIH) grants DK109134 and DK123492 (L.J.H.), NiIDDK Diabetes Complications Consortium (RRID:SCR-001415; DK076169, DK115255); UL1 TR002377 (L.J.H.; Mayo Clinic CCA Study UL1TR002377; REDCap), and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (L.J.H.). Additional support was provided by NIH grants DK102325 (LOL), DK07013 (SMC), Burroughs Wellcome Fund (SMC); DK118120 (SMH); DK101405 (nuSURF: Mayo; J.M.M.; G.B.B.); Summer Program for International Research Internship Training (SPIRIT) Alfaisal University, Riyadh, Saudi Arabia (AT). Publication content is solely the responsibility of the authors and does not necessarily represent the official views of Satellite Healthcare, Regenerative Medicine Minnesota, or the NIH.

CONFLICT OF INTEREST

L.O.L. received grant funding from Novo Nordisk and is an advisor to Weijian Technologies and AstraZeneca. All other authors declared no financial conflicts of interest.

AUTHOR CONTRIBUTIONS

L.J.H.: designed the study, carried out the reviews, analyzed the data, created figures, drafted and revised the paper, critically reviewed and edited the paper; G.B.-B.: carried out the reviews, abstracted data, analyzed the data, created figures, drafted and revised the paper, critically reviewed and edited the paper; X.B.: carried out the reviews, abstracted data, critically reviewed and edited the paper; T.A.: carried out the reviews, abstracted data, drafted and revised the paper, critically reviewed and edited the paper; J.M.M.: carried out the reviews, drafted and revised the paper, critically reviewed and edited the paper; S.M.C., X.Z., S.M.H., A.K.: carried out the reviews, critically reviewed and edited the paper; J.M.M.: abstracted data, analyzed the data, drafted and revised the paper, critically reviewed and edited the paper; M.H.M.: analyzed the data, drafted and revised the paper, critically reviewed and edited the paper; E.C.L., S.R.K., B.T., L.O.L.: critically reviewed and edited the paper; All authors approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT

Data relevant to the study are included in the article or uploaded as Supporting Information.

ORCID

LaTonya J. Hickson \( \text{https://orcid.org/0000-0002-7485-336X} \)

Lilach O. Lerman \( \text{https://orcid.org/0000-0002-3271-3887} \)

REFERENCES

1. Saran R, Robinson B, Abbott KC, et al. U.S. renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71(3 suppl 1):A7.

2. Ezquer F, Ezquer M, Simon V, et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant. 2009;15(11):1354-1365.

3. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Blood Marrow Transplant. 2008;14(6):631-640.

4. Fang Y, Tian X, Bai S, et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med. 2012;30(1):85-92.

5. Pan XH, Yang XY, Yao X, et al. Bone-marrow mesenchymal stem cell transplantation to treat diabetic nephropathy in tree shrews. Cell Biochem Funct. 2014;32(5):453-463.

6. Papazova DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA, Verhaar MC. Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis. Dis Model Mech. 2015;8(3):281-293.
11. Hickson LJ, Eirin A, Lerman LO. Challenges and opportunities for regenerative therapy for diabetic nephropathy. *Kidney Int*. 2016;89(4):767-778.

12. Sattwikka PD, Mustafa R, Paramaswari A, Herningyts AH. Stem cells for lupus nephritis: a concise review of current knowledge. *Lupus*. 2018;27(12):1881-1897.

13. Hanza AH, Al-Bishi WM, Damati LA, Ahmed HH. Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy. *Ren Fail*. 2017;39(1):67-76.

14. Lang H, Dai C. Effects of bone marrow mesenchymal stem cells on plasminogen activator inhibitor-1 and renal fibrosis in rats with diabetic nephropathy. *Arch Med Res*. 2016;47(2):71-77.

15. Lang H, Hu J, Tian ZG, Yang X, Cao Y, Li WG. Cell-based therapies for experimental diabetic nephropathy: a systematic review and meta-analysis. *J Biol Regul Homeost Agents*. 2016;30(4):1047-1051.

16. Ezquer F, Giraud-Billoud M, Carpio D, Cabezas F, Conget P, Ezquer M. Preregenerative microenvironment triggered by donor mesenchymal stem cells preserves renal function and structure in mice with severe diabetes mellitus. *Biomed Res Int*. 2015;2015:164703.

17. Lee KW, Kim TM, Kim KS, et al. Renal ischemia-reperfusion injury in a diabetic monkey model and therapeutic testing of human bone marrow-derived mesenchymal stem cells. *J Diabetes Res*. 2018;2018:5182606.

18. Niu W, Fang Y, Xie L, et al. Adipose-derived mesenchymal stem cells transplantation alleviates renal injury in streptozotocin-induced diabetic nephropathy. *Histochem Cytochem*. 2015;63(11):842-853.

19. Paulini J, Higuti E, Bastos RM, Gomes SA, Rangel EB. Mesenchymal stem cells as therapeutic candidates for halting the progression of diabetic nephropathy. *Stem Cells Transl Med*. 2016;5(6):1952-1969.

20. Tang Q, Wu H, Lei J, et al. HIF1α deletion facilitates adipose stem cells to repair renal fibrosis in diabetic mice. *In Vitro Cell Dev Biol Anim*. 2018;54(4):272-286.

21. Zhong L, Liao G, Wang X, et al. Mesenchymal stem cells microvesicle-miR-451a ameliorate early diabetic kidney injury by negative regulation of P15 and P19. *Exp Biol Med*. 2018;243(15-16):1233-1242.

22. Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. *EBioMedicine*. 2016;12:263-269.

23. Griffin TP, Martin WP, Islam N, O’Brien T, Griffin MD. The promise of mesenchymal stem cell therapy for diabetic kidney disease. *Curr Diab Rep*. 2016;16(5):42.

24. Bai Y, Wang J, He Z, Yang M, Li L, Jiang H. Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor beta (TGF-beta)/smad pathway and pro-inflammatory cytokines. *Med Sci Monit*. 2019;25:3069-3076.

25. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow hom to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. *Proc Natl Acad Sci USA*. 2006;103(46):17438-17443.

26. Li H, Rong P, Ma X, et al. Paracrine effect of mesenchymal stem cell as a novel therapeutic strategy for diabetic nephropathy. *Life Sci*. 2018;215:113-118.

27. Lv S, Liu G, Sun A, et al. Mesenchymal stem cells ameliorate diabetic glomerular fibrosis in vivo and in vitro by inhibiting TGF-beta signaling via secretion of bone morphogenetic protein 7. *Diab Vasc Dis Res*. 2014;11(4):251-261.

28. Lv SS, Liu G, Wang JP, et al. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration. *Int Immunopharmacol*. 2013;17(2):275-282.

29. Zhang L, Li K, Liu X, et al. Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats. *Stem Cells Dev*. 2013;22(23):3074-3086.

30. Castiglione RC, Maron-Gutierrez T, Barbosa CML, et al. Bone marrow-derived mononuclear cells promote improvement in glomerular function in rats with early diabetic nephropathy. *Cell Physiol Biochem*. 2013;32(3):699-718.

31. Guimaraes ET, Cruz Gda S, Almeida TF, et al. Transplantation of stem cells obtained from murine dental pulp improves pancreatic damage, renal function, and painful diabetic neuropathy in diabetic type 1 mouse model. *Cell Transplant*. 2013;22(12):2345-2354.

32. Hsieh CC, Lin CL, He JT, et al. Administration of cytokine-induced myeloid-derived suppressor cells ameliorates renal fibrosis in diabetic mice. *Stem Cell Res Ther*. 2018;9(1):183.

33. Kelley R, Bruce A, Spencer T, et al. A population of selected renal cells augments renal function and extends survival in the ZSF1 model of progressive diabetic nephropathy. *Cell Transplant*. 2013;22(6):1023-1039.

34. Maldonado M, Huang TH, Yang L, Xu L, Ma L. Human umbilical cord Wharton jelly cells promote extra-pancreatic insulin formation and repair of renal damage in STZ-induced diabetic mice. *Cell Commun Signal*. 2017;15:43.

35. Wang S, Li Y, Zhao J, Zhang J, Huang Y. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. *Bioi Blood Marrow Transplant*. 2013;19(4):538-546.

36. Wang Y, He J, Pei X, Zhao W. Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function and extends survival in the ZSF1 model of progressive diabetic nephropathy. *Diabetes Res Clin Pract*. 2013;22(6):1023-1039.

37. Maldonado M, Huang TH, Yang L, Xu L, Ma L. Human umbilical cord Wharton jelly cells promote extra-pancreatic insulin formation and repair of renal damage in STZ-induced diabetic mice. *Cell Commun Signal*. 2017;15:43.

38. Wang S, Li Y, Zhao J, Zhang J, Huang Y. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. *Bioi Blood Marrow Transplant*. 2013;19(4):538-546.

39. Wang Y, He J, Pei X, Zhao W. Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models. *Nephrology*. 2013;18(3):201-208.

40. Ebrahim N, Ahmed IA, Hussien NI, et al. Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway. *Cell Biol Chem*. 2018;12(22):226.

41. Grange C, Tritt S, Tapparo M, et al. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. *Sci Rep*. 2019;9(1):4468.

42. Jiang ZZ, Liu YM, Niu X, et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. *Stem Cell Res Ther*. 2016;7:24.

43. Nagashii K, Mizue Y, Chikeni T, et al. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. *Sci Rep*. 2016;6:34842.
as result of oxidative stress and autophagy may limit their potential therapeutic use. Stem Cell Rev Rep. 2018;14(3):337-345.

44. van de Vyver M. Intrinsic mesenchymal stem cell dysfunction in diabetes mellitus: implications for autologous cell therapy. Stem Cells Dev. 2017;26(14):1042-1053.

45. Hickson LJ, Eirin A, Conley SM, et al. Diabetic kidney disease alters the transcriptome and function of human adipose-derived mesenchymal stromal cells but maintains immunomodulatory and paracrine activities important for renal repair. Diabetes. 2021. https://doi.org/10.2337/db19-1268. Epub ahead of print. PMID: 33858824.

46. Nagashii K, Mizue Y, Chikenji T, et al. Umbilical cord extracts improve diabetic abnormalities in bone marrow-derived mesenchymal stem cells and increase their therapeutic effects on diabetic nephropathy. Sci Rep. 2017;7(1):8484.

47. Rashed LA, Elattar S, Eltablawy N, Ashour H, Mahmoud LM, El-Esawy Y. Mesenchymal stem cells pretreated with melatonin ameliorate kidney functions in a rat model of diabetic nephropathy. Biochem Cell Biol. 2018;96(5):564-571.

48. Sun J, Zhao F, Zhang W, Lv J, Yin A. BMSCs and miR-124a ameliorate diabetic nephropathy via inhibiting notch signalling pathway. J Cell Mol Med. 2018;22(10):4840-4855.

49. Zhang Y, Ye C, Wang G, et al. Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats. Biomed Res Int. 2013;2013:526367.

50. Zhang Y, Yuan DA, Advani A, et al. Early-outgrowth bone marrow attenuated renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes. 2012;61(8):2114-2125.

51. Zhou H, Tian HM, Long Y, et al. Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J. 2009;122(21):2573-2579.

52. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.

53. Wever KE, Menting TP, Rovers M, et al. Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis. PLoS One. 2012;7(2):e32296.

54. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(43).

55. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analyses. Biormetrics. 2000;56(2):455-463.

56. Murad MH, Wang Z, Chu H, Lin L. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ. 2019;364:k4817.

57. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.

58. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.

59. Gan J, Wang Y, Zhou X. Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: a meta-analysis. Exp Ther Med. 2018;16(6):4479-4492.

60. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.

61. Abdel Aziz MT, Wassaf MA, Ahmed HH, et al. The role of bone marrow derived-mesenchymal stem cells in attenuation of kidney function in rats with diabetic nephropathy. Diabetes Metab Syndr. 2014;6(1):34.

62. Jha JC, Gray SP, Barit D, et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol. 2014;25(6):1237-1254.

63. He X, Zhang T, Tolosa M, et al. A new, easily generated mouse model of diabetic kidney fibrosis. Sci Rep. 2019;9(1):12549.

64. Pagatalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342-348.

65. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007;56(8):2155-2160.

66. Weil EJ, Lemley KV, Mason CC, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int. 2012;82(9):1010-1017.

67. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50(11):2398-2404.

68. Harlan SM, Heinz-Taheny KM, Sullivan JM, et al. Progressive renal disease established by renin-coding adeno-associated virus-driven hypertension in diverse diabetic models. J Am Soc Nephrol. 2018;29(2):477-491.

69. Heuer JG, Harlan SM, Yang DD, et al. Role of TGF-alpha in the progression of diabetic kidney disease. Am J Physiol Renal Physiol. 2017;312(6):F951-F962.

70. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA. 2000;97(14):8015-8020.

71. Wang B, Koh P, Winbanks C, et al. miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes. 2011;60(1):280-287.

72. Xavier S, Vasko R, Matsumoto K, et al. Curtailing endothelial TGF-beta signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J Am Soc Nephrol. 2015;26(4):817-829.

73. Dong R, Yu J, Yu F, Yang S, Qian Q, Zha Y. IGF-1/IGF-1R blockade ameliorates diabetic kidney disease through normalizing Snail1 expression in a mouse model. Am J Physiol Endocrinol Metab. 2019;317(4):E686-E698.

74. Dai HY, Zheng M, Tang RN, et al. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy. Am J Med Sci. 2011;341(3):207-214.

75. Zhang H, Nair V, Saha J, et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. Kidney Int. 2017;92(4):909-921.

76. Yasuda H, Tochigi Y, Katayama K, Suzuki H. Progression of renal fibrosis in congenital CKD model rats with reduced number of nephrons. Exp Toxicol Pathol. 2017;69(5):245-258.

77. author>Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20(1):1-17.

78. Su Z, Widomski D, Ma J, et al. Longitudinal changes in measured glomerular filtration rate, renal fibrosis and biomarkers in a rat model of type 2 diabetic nephropathy. Am J Pathol. 2016;184(5):1397-1405.

79. Remuzzi A, Puntorieri S, Mazzoleni A, Remuzzi G. Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. Kidney Int. 1988;34(4):481-486.

80. Breyer MD, Bottening E, Brosius FC 3rd, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16(1):27-45.

81. Brosius FC 3rd, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503-2512.

82. Path G, Perakakis N, Mantzoros CS, Seufert J. Stem cells in the treatment of diabetes mellitus - focus on mesenchymal stem cells. Metabolism. 2019;90:1-15.

83. Cossu G, Birchall M, Brown T, et al. Lancet commission: stem cells and regenerative medicine. Lancet. 2018;391(10123):883-910.
84. El-Ashmawy NE, Khedr EG, El-Bahrawy HA, El-Berashy SA. Effect of human umbilical cord blood-derived mononuclear cells on diabetic nephropathy in rats. *Biomed Pharmacother*. 2018;97:1040-1045.

85. Masoad RE, Ewais MM, Tawfik MK, Abd El-All HS. Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats. *Pharmacol Rep*. 2012;64(5):1223-1233.

86. Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. *World J Stem Cells*. 2014;6(2):195-202.

87. Park JH, Park J, Hwang SH, Han H, Ha H. Delayed treatment with human umbilical cord blood-derived stem cells attenuates diabetic renal injury. *Transplant Proc*. 2012;44(4):1123-1126.

88. Eirin A, Zhu XY, Krier JD, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. *STEM CELLS*. 2012;30(5):1030-1041.

89. Sood V, Mittal BR, Bhansali A, et al. Biodistribution of 18F-FDG-labeled autologous bone marrow-derived stem cells in patients with type 2 diabetes mellitus: exploring targeted and intravenous routes of delivery. *Clin Nucl Med*. 2015;40(9):697-700.

90. Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. *J Am Soc Nephrol*. 2005;16(1):68-78.

91. Li B, Leung JCK, Chan LYY, et al. Amelioration of endoplasmic reticulum stress by mesenchymal stem cells via hepatocyte growth factor/c-met signaling in obesity-associated kidney injury. *STEM CELLS TRANSLATIONAL MEDICINE*. 2019;8(9):898-910.

92. Li L, Baroja ML, Majumdar A, et al. Human embryonic stem cells possess immune-privileged properties. *STEM CELLS*. 2004;22(4):448-456.

93. Drukker M, Katchman H, Katz G, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. *STEM CELLS*. 2006;24(2):221-229.

94. Rossignol J, Boyer C, Thinard R, et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. *J Cell Mol Med*. 2009;13(8b):2547-2558.

95. Torres Crigna A, Daniele C, Gamez C, et al. Stem/stromal cells for treatment of kidney injuries with focus on preclinical models. *Front Med*. 2018;5:179.

96. Azushima K, Gurley SB, Coffman TM. Modelling diabetic nephropathy in mice. *Nat Rev Nephrol*. 2018;14(1):48-56.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Hickson LJ, Abedalqader T, Ben-Bernard G, et al. A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease. *STEM CELLS Transl Med*. 2021;10(9):1304–1319. [https://doi.org/10.1002/sctm.19-0419](https://doi.org/10.1002/sctm.19-0419)